Related Experiment Video
Updated: Oct 16, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Nanocarrier Systems for Nystatin Delivery: Formulation Performance and Therapeutic Implications in Candidiasis
Evi Sulastri1,2, Maya Nurul Rahma1, Khaled M Elamin3
1Department of Pharmaceutics and Pharmaceutical Technology, Universitas Padjadjaran, Sumedang 45363, West Java, Indonesia.
Abstract:
Nystatin is a commonly used antifungal medicine for the treatment of candidiasis, particularly in superficial and mucosal infections. Its clinical usefulness is limited by poor water solubility, instability, a short residence time in the mucosa, and low absorption. This review critically evaluates 22 eligible studies (PRISMA 2020-compliant search, January 2004-December 2025) on nano- and microparticulate delivery systems for nystatin in the treatment of candidiasis, using a novel analytical framework that maps nanocarrier physicochemical properties to site-specific delivery requirements across oral, cutaneous, and vulvovaginal candidiasis. Nanoemulsions, nanosuspensions, Solid Lipid Nanoparticles (SLN), Nanostructured Lipid Carriers (NLC), polymeric nanoparticles, and vesicular systems, specifically liposomes and nanocubosomes, are evaluated by standardized physicochemical parameters, evidence-graded antifungal endpoints, and a translational readiness evaluation. Nanoemulsions and NLCs demonstrate the most favorable translational profiles. Challenges related to manufacturing scalability, long-term stability, and regulatory acceptance remain barriers to clinical translation.
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Site-Targeted
Antifungal Agents
Candidiasis
Ophthalmic Drug Delivery Systems
Oral Drug Delivery Systems: Introduction

